In the opening quarter of 2025, Verastem (VSTM, Financial) Oncology has achieved significant milestones in its pipeline initiatives. The company has exercised an early option to license VS-7375 from GenFleet Therapeutics. Moreover, they have completed patient enrollment for initial cohorts in the RAMP 205 clinical trial targeting first-line metastatic pancreatic cancer and are continuing patient recruitment for the RAMP 203 clinical trial, which focuses on advanced KRAS G12C mutant non-small cell lung cancer.
With its financial foundation strengthened, the company anticipates a pivotal second quarter. This includes the expected FDA approval and market launch of the AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. Additionally, plans are in place to begin a Phase 1/2a trial in the United States for VS-7375, recognized as a promising oral KRAS G12D (ON/OFF) inhibitor, by mid-2025. Verastem also aims to present updated data for both VS-7375 and RAMP 205 at the ASCO conference.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Verastem Inc (VSTM, Financial) is $15.25 with a high estimate of $20.00 and a low estimate of $10.00. The average target implies an upside of 104.42% from the current price of $7.46. More detailed estimate data can be found on the Verastem Inc (VSTM) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Verastem Inc's (VSTM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
